← Back to headlines
Mesoblast Stock Rises After FDA Clears Ryoncil Study for Duchenne
Mesoblast shares saw gains following the FDA's clearance for a study to test its drug Ryoncil in treating Duchenne muscular dystrophy.
8 Apr, 11:26 — 8 Apr, 11:26
Sources
Showing 1 of 1 sources
Related Stories
Manila Water prepares for summer heat and high demand
just now
Philippines Announces Results of April 2026 Physicians Licensure Examination
just now
Pagasa flags 2 areas for dangerous heat index levels on April 9
just now
Philippines Experiences High Heat Index, DOH Issues Warnings as Areas Log Danger Levels
just now